YD Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	0.51	0.35	0.36
Revenue Growth (YoY)	45.76%	-3.84%	-
Cost of Revenue	0.36	0.2	0.23
Gross Profit	0.16	0.15	0.13
Selling, General & Admin	1.13	0.16	0.18
Research & Development	0.49	-	-
Operating Expenses	1.62	0.16	0.18
Operating Income	-1.46	-0.01	-0.04
Interest Expense	-0	-0	-0
Interest & Investment Income	0.01	0	0
Other Non Operating Income (Expenses)	0.06	0.03	0.06
EBT Excluding Unusual Items	-1.39	0.02	0.01
Gain (Loss) on Sale of Investments	-	-	-0.06
Pretax Income	-1.39	0.02	-0.05
Income Tax Expense	0.03	0	0
Net Income	-1.41	0.01	-0.05
Net Income to Common	-1.41	0.01	-0.05
Shares Outstanding (Basic)	1	1	-
Shares Outstanding (Diluted)	1	1	-
Shares Change (YoY)	4.01%	-	-
EPS (Basic)	-1.29	0.01	-
EPS (Diluted)	-1.29	0.01	-
Free Cash Flow	-1.91	-0.06	0.07
Free Cash Flow Per Share	-1.75	-0.05	-
Gross Margin	30.44%	43.82%	36.58%
Operating Margin	-286.45%	-2.81%	-12.33%
Profit Margin	-276.58%	3.87%	-13.95%
Free Cash Flow Margin	-374.58%	-15.98%	19.21%
EBITDA	-1.36	-0.01	-0.04
EBITDA Margin	-265.93%	-2.11%	-11.34%
D&A For EBITDA	0.1	0	0
EBIT	-1.46	-0.01	-0.04
EBIT Margin	-286.45%	-2.81%	-12.33%
Effective Tax Rate	-	23.17%	-

Updated Apr 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q